XBiotech Inc (XBIT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, XBiotech Inc (XBIT) has a cash flow conversion efficiency ratio of -0.025x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.26 Million) by net assets ($167.08 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
XBiotech Inc - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how XBiotech Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read XBIT total debt and obligations for a breakdown of total debt and financial obligations.
XBiotech Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of XBiotech Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
EDU Holdings Ltd
AU:EDU
|
0.191x |
|
United Radiant Technology
TWO:5315
|
-0.018x |
|
DMCC SPECIALITY CHEMICALS LIMITED
NSE:DMCC
|
0.033x |
|
TEKNA HOLDING ASA NK 2
F:8VB
|
N/A |
|
Spirit Technology Solutions Ltd
AU:ST1
|
-0.027x |
|
XCF Global, Inc. Class A Common Stock
NASDAQ:SAFX
|
-1.000x |
|
SRV Group plc
HE:SRV1V
|
0.076x |
|
Kron Telekomunikasyon Hizmetleri AS
IS:KRONT
|
0.156x |
Annual Cash Flow Conversion Efficiency for XBiotech Inc (2012–2024)
The table below shows the annual cash flow conversion efficiency of XBiotech Inc from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see XBiotech Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $182.27 Million | $-30.96 Million | -0.170x | -98.54% |
| 2023-12-31 | $218.85 Million | $-18.73 Million | -0.086x | -38.76% |
| 2022-12-31 | $240.40 Million | $-14.82 Million | -0.062x | -123.92% |
| 2021-12-31 | $269.38 Million | $69.44 Million | 0.258x | +237.95% |
| 2020-12-31 | $348.64 Million | $-65.15 Million | -0.187x | -672.86% |
| 2019-12-31 | $755.63 Million | $-18.27 Million | -0.024x | +93.95% |
| 2018-12-31 | $41.40 Million | $-16.54 Million | -0.399x | +28.58% |
| 2017-12-31 | $60.16 Million | $-33.65 Million | -0.559x | +28.21% |
| 2016-12-31 | $59.06 Million | $-46.02 Million | -0.779x | -141.03% |
| 2015-12-31 | $103.05 Million | $-33.31 Million | -0.323x | -63.08% |
| 2014-12-31 | $59.03 Million | $-11.70 Million | -0.198x | +77.24% |
| 2013-12-31 | $10.23 Million | $-8.91 Million | -0.871x | +44.81% |
| 2012-12-31 | $7.37 Million | $-11.63 Million | -1.578x | -- |
About XBiotech Inc
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes true human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases. The company is also developing interleukin-1 alpha therapies to various medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates t… Read more